Previous Close | 417.32 |
Open | 419.48 |
Bid | 420.03 x 100 |
Ask | 420.95 x 100 |
Day's Range | 415.06 - 420.67 |
52 Week Range | 310.90 - 448.40 |
Volume | |
Avg. Volume | 1,315,203 |
Market Cap | 108.639B |
Beta (5Y Monthly) | 0.35 |
PE Ratio (TTM) | 30.26 |
EPS (TTM) | 13.90 |
Earnings Date | Apr 29, 2024 - May 03, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 464.98 |
Subscribe to Yahoo Finance Plus to view Fair Value for VRTX
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day.
While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.
Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month.